News

Orexo is planning to start and conclude the next clinical study in healthy volunteers in the fourth quarter of 2011. Orexo president and CEO Anders Lundstrom said OX27

The company’s decision follows two years of expansion and investment in a £15m laboratory in Cardiff. Quotient Bioresearch, a provider of early stage drug development services to pharmaceutical

Suzhou Erye is a subsidiary of NeoStem, which is engaged in the development and manufacturing of cell-based therapies in the US. The combined production lines now certified by

The drug delivery system is a two-compartment, flexible, eco-friendly IV container that stores pre-measured drug and diluent doses. DUPLEX can be stored at room temperature and fits in

The companies can now offer marketing and commercialization rights for Ondansetron ODF in Europe and selected Non-European countries, either through global, regional or local license agreements. Ondansetron ODF

Following the acquisition, inVentiv Health’s clinical segment comprises i3, along with inVentiv’s existing clinical businesses and PharmaNet Development Group. i3 CEO Glenn Bilawsky said for their clients, this

Zutripro oral solution and Rezira oral solution, to be marketed by Cypress Pharma’s subsidiary Hawthorn Pharmaceuticals, are indicated for the treatment of cough and other symptoms linked with

The partnership addresses the industry need for IRTsolutions to optimize clinical trial patient randomization, drug supply management and clinical trial status monitoring and reporting. FormsVision was formed to

The company expects to recruit around 880 patients in over 40 hospitals in 9 countries. The aim of this study is to establish Multikine as a first-line standard